U.S. Court in Massachusetts Orders Janssen to Produce Communications with DOJ, OIG in Whistleblower Kickback Action
- March 17, 2023
A federal court in Massachusetts gave Janssen Biotech, Inc. two weeks to produce its ex parte communications with federal enforcement agencies related to a qui tam action alleging the pharmaceutical company violated the Anti-Kickback Statute and caused the submission of false claims by providing free business advisory services to physicians who prescribed its infusible drugs, Remicade and Simponi ARIA.
ARTICLE TAGS
You must be logged in to access this content.